Biotech & AI Consulting
Ensemble Group Holdings combines pioneering expertise in radiogenomics, medical AI, and drug discovery to help biotech and pharmaceutical companies make smarter decisions faster.
Right Target → Right Molecule → Right Patient → Right Test
What We Do
Specialized consulting at the intersection of biotechnology, clinical science, and artificial intelligence.
We provide rigorous, mechanism-based assessments of drug programs to help investors and pharma partners make informed decisions. Our proprietary analytical frameworks integrate structural biology, biophysics, and multi-dimensional clinical data to answer the questions: "Why and Where will this drug succeed or fail?"
Q1: Is it disease-modifying?
Does the drug exert sufficient biophysical control to drive durable disease modification? Or is it just moving a biomarker without changing outcomes?
Q2: In which patients?
Have we identified the patient ecosystem where this mechanism is a critical dependency? With a recruitable biomarker for trial enrollment?
"We identify WHERE in the causal chain assumptions are unvalidated — before Phase 3 investment."
We apply advanced computational methods to accelerate therapeutic design. Our capabilities span small molecules, peptides, antibodies, and process optimization.
We have designed, validated, and deployed clinical AI systems at scale. Our experience includes multi-center international trials and production deployment across national healthcare systems.
Our AI systems are currently deployed in production across an entire national healthcare system, serving millions of patients.
Dr. Kuo founded the field of radiogenomics — the integration of multi-scale and multi-modal data types to enable discovery of deep, contextual, non-invasive biomarkers. This pioneering work, published in Nature Biotechnology and PNAS, initially established how imaging can decode molecular signatures of disease.
How We Work
Designing therapeutics that impose biophysical control over disease biology — not just target binding.
Clinical de-risking for your therapeutic — validating assumptions before Phase 3 investment.
TARGET ID
MOLECULE DEV
PK/PD
PRE-IND
PHASE 1
PHASE 2
PHASE 3
FILING
Where We Insert
Beyond here: capital committed
"The fusion of multi-scale data enables exponential, not linear, insight, enabling us to identify WHERE in the causal chain assumptions are unvalidated — before Phase 3 investment."
The Two Questions Every Drug Must Answer
Q1: Is it disease-modifying?
Biophysical control for durable change
Drives: state selection, mechanism design, resistance prediction, durability engineering
Q2: In which patients?
Patient ecosystem where mechanism matters
Drives: context mapping, biomarker selection, trial design, stratification strategy
"Q1 + Q2 don't just validate — they drive design from Day 1"
Target ID
Literature, genetics
Screening
HTS, phage, DEL
Hit-to-Lead
Binding, selectivity
Lead Opt
Med chem, ADMET
PK/PD
In vivo
THEN ask:
Q1? Q2?
(Often too late)
Problem: Optimizes for assay metrics, discovers clinical issues downstream
We can augment your traditional path OR provide AI-guided rational design
Your CRO runs screens & assays — We add Q1+Q2 intelligence at each step
Replace/compress traditional cascade — Design with Q1+Q2 from first principles
Target exists in multiple states. We model which are disease-relevant and design to those.
→ Informs Q1: mechanism
Predict resistance, bypass, and escape trajectories. Design durability into molecule.
→ Informs Q1: durable modification
Map where mechanism is a critical dependency — by patient context, not average.
→ Informs Q2: which patients
These aren't separate steps — they're integrated into every design decision
Traditional: Design for metrics → ask clinical questions later → surprises at Phase 2
Ensemble: Q1 + Q2 drive design from Day 1 → know your answer before capital is committed
This integration is what startups and CROs don't have —
the ability to design with clinical reality built in, not bolted on.
Anonymized case studies demonstrating our first principles driven integrated approach with outcomes, are available upon request.
Our Impact
A proven history of delivering measurable outcomes at the intersection of science, technology, and patient care.
0
Peer-Reviewed Publications
0
Biotech Exits
0
Drug Candidates in Phase 1/2 Clinical Trials
0
Patients Served by AI
Small molecule drug discovery company and full-service therapeutics CRO
Acquired by Aclaris Therapeutics (NASDAQ: ACLR), 2017
4 drug candidates now in Phase 1/2 clinical trials
Pre-IND immuno-oncology therapeutics company
Acquired by Lymbus Oncology, 2020
Computer vision system for emergency X-ray interpretation
Deployed across all Hong Kong Hospital Authority EDs since 2023
Serving 7+ million patients territory-wide
Deep learning for SARS-CoV-2 detection from chest X-ray
Multi-center, 4-country international validation trial
Published in European Radiology
Alexander R. Margulis Award
RSNA's highest research honor, 2016
Gold Medal
RSNA AI Competition, 2022
First Place
Novo Nordisk / Innocentive Challenge, 2020
Gary Becker Young Investigator
Award, 2006
Independent Research
Computation-driven analysis of drug mechanisms, resistance prediction, and biotech investment implications for targeted therapeutics. Published bimonthly on Substack.
Flagship analyses of drug mechanisms, resistance prediction frameworks, and biotech investment implications — spanning kinase inhibitors, targeted biologics, and emerging therapeutic modalities.
Full computational depth, engine-generated insights, resistance and risk landscape assessments, and early access to new analyses powered by molecular dynamics, evolutionary modeling, and structural biology.
Who We Are
Founder & Managing Partner
Dr. Michael Kuo is a physician-scientist and entrepreneur who founded the field of radiogenomics.
He has built and sold two drug discovery companies: Confluence Life Sciences (acquired by Aclaris Therapeutics, NASDAQ: ACLR) and Achilles Biotherapeutics (acquired by Lymbus Oncology), as well as the therapeutics contract research organization (CRO) Confluence Discovery Technologies (now a sub-unit of Aclaris Therapeutics). Through these ventures, he helped developed 5 drug candidates now in, or progressing towards clinical trials and built a full-service therapeutics CRO from the ground up.
At the University of Hong Kong, Dr. Kuo founded the Medical AI Laboratory (MAIL) and led the development of clinical AI systems now fully integrated and deployed at national scale, including a hip fracture detection system serving all emergency departments across Hong Kong.
With 87+ peer-reviewed publications, an H-index of 35, and 178+ invited lectures globally, Dr. Kuo brings unparalleled scientific credibility. Combined with his entrepreneurial track record and AI deployment experience, he offers clients a rare combination of deep expertise and proven execution.
MD, Baylor College of Medicine
Interventional Radiology Fellowship, Stanford University
Diagnostic Radiology Residency, Stanford University
Clinical Faculty, Stanford University VA Hospitals
Fmr. Associate Professor, UCLA (Radiology, Pathology, Bioengineering)
Fmr. Assistant Professor, UC San Diego
Fmr. Visiting Professor, University of Hong Kong
Let's Connect
Whether you're evaluating a drug program, building clinical AI, or seeking strategic advisory in computational biology, we'd like to hear from you.
[email protected]